Related Experiment Videos
The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines
J Rodriguez-Vicente1, V Vicente-Ortega, M Canteras-Jordana
1Department of Pathology, Faculty of Medicine, University of Murcia, Spain.
Background:
The chemotherapy of melanoma patients must be improved because of the naturally poor response and acquired resistance of this disease.
Methods:
The authors used mouse (B16F10) and human (SK-MEL-28 and SK-MEL-1) melanoma lines for in vitro treatment with melphalan, lomustine, fotemustine, and 4-hydroxyanisole (4-HA) alone, combined and after pretreatment with buthionine sulfoximine (BSO), ethacrynic acid (EA), and azelaic acid (AZA).
Results:
Melphalan was the most effective individual drug, followed by lomustine, fotemustine, and 4-HA. The simultaneous administration of two agents was disappointing, although some combinations slightly improved the response compared with the individual treatments. Pretreatment with BSO enhanced the cytotoxicity of melphalan and lomustine 10-fold in B16F10 and 7.5-fold in SK-MEL-28, increasing the toxicity of fotemustine in all 3 lines. EA potentiated lomustine and fotemustine 9-fold and melphalan 5-fold in B16F10 and SK-MEL-28. AZA increased the effectiveness of lomustine and fotemustine in B16F10 and to a lower degree in the two human lines. 4-HA was the poorest drug for sensitization; only B16F10 BSO followed by 4-HA treatment demonstrated increased toxicity, and all other combinations with 4-HA were negative or antagonistic. There was a strong relationship between dopa oxidase activity and the toxicity of 4-HA.
Conclusions:
B16F10 was the most sensitive to all treatments and SK-MEL-1 the most resistant. Melphalan was the most active individual drug and 4-HA the least. Combinations of two drugs did not result in improved activity compared with drugs administered alone. Pretreatment with modulator seems to be a potential method for enhancing some treatments.
Insights
Chemotherapy for melanoma needs improvement due to poor response and resistance. Pre-treating melanoma cells with agents like buthionine sulfoximine (BSO) significantly enhanced the effectiveness of certain chemotherapy drugs, offering a potential strategy to improve treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Melanoma exhibits naturally poor response to chemotherapy.
- Acquired resistance further complicates treatment efficacy in melanoma patients.
Purpose of the Study:
- To evaluate the efficacy of single-agent chemotherapy drugs.
- To investigate the effects of drug combinations and modulators on melanoma cell lines.
- To identify potential strategies for overcoming chemotherapy resistance in melanoma.
Main Methods:
- In vitro treatment of mouse (B16F10) and human (SK-MEL-28, SK-MEL-1) melanoma cell lines.
- Utilized melphalan, lomustine, fotemustine, and 4-hydroxyanisole (4-HA) as chemotherapeutic agents.
- Investigated the impact of pre-treatment with buthionine sulfoximine (BSO), ethacrynic acid (EA), and azelaic acid (AZA) on drug cytotoxicity.
Main Results:
- Melphalan demonstrated the highest individual drug efficacy, followed by lomustine and fotemustine.
- Simultaneous drug administration yielded disappointing results, with limited improvement over single agents.
- Pre-treatment with BSO, EA, and AZA significantly enhanced the cytotoxicity of melphalan, lomustine, and fotemustine in various melanoma cell lines.
- 4-hydroxyanisole (4-HA) showed poor sensitization capabilities, with antagonistic effects in most combinations.
Conclusions:
- Melphalan is the most potent individual chemotherapy drug tested against melanoma.
- Modulator pre-treatment represents a promising approach to enhance the efficacy of specific chemotherapy regimens.
- Drug combinations were generally less effective than enhanced single-agent treatments.